Selank for Health & Longevity - Quick Reference Sheet

Selank for Health & Longevity

Created on 08/06/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

Selank is a stabilised version of a natural immune-signalling peptide, registered in Russia as a nasal treatment for anxiety. Its most consistently reported effect is symptom reduction in people with diagnosed anxiety, without reported drowsiness, memory dulling, or dependence. Effects on mood, drive, and inflammation rest on thinner evidence. Outside Russia no approved product exists; long-term human data are absent. (Full Review)

Protocol

Standard registered protocol
2 drops into each nostril, three times daily
0.15% nasal solution; approximately 300 micrograms per administration and 900 micrograms per day, for a course of 14 days
Single versus split dosing
Split
The registered protocol divides the daily dose into three administrations; more than 2 to 3 drops per nostril runs off
Best time of day
Morning and early afternoon
Last dose in the late afternoon; the reported mildly activating component argues against evening dosing
Time to effect
Anxiety reduction
Within the first days
Rapid-responder subgroup within roughly three days; full effect established across the 14-day course
Calm and mental clarity
1 to 2 weeks
Placed in this window by practitioner reports rather than trial data
Cognitive effects
4 to 6 weeks
Where they occur; from practitioner reports

Benefits

Contraindications
  • Pregnancy and lactation
  • Anyone under 18
  • Active malignancy of any stage, and the first five years after treatment for a haematological malignancy
  • Active autoimmune disease requiring treatment (systemic lupus erythematosus, rheumatoid arthritis with active synovitis, inflammatory bowel disease in flare)
  • Solid organ transplant recipients on any immunosuppressive regimen
  • Therapeutic anticoagulation, platelet count below 100,000 per microlitre, or known bleeding disorder
  • Documented sedative, benzodiazepine, opioid, or alcohol use disorder (active or in remission within 12 months)
  • Severe hepatic impairment (Child-Pugh Class B or C) or advanced kidney disease (estimated glomerular filtration rate below 30 mL/min/1.73 m²)
  • Chronic rhinosinusitis, nasal polyposis, or nasal or sinus surgery within 90 days
Key Interactions
  • Benzodiazepines (diazepam, phenazepam, alprazolam, clonazepam, lorazepam)
  • Phenibut and other GABA-active recreational compounds
  • Alcohol
  • Sedating antihistamines (diphenhydramine, doxylamine, chlorphenamine)
  • Nasal decongestant sprays (oxymetazoline, xylometazoline) and intranasal corticosteroids (fluticasone, mometasone)
  • Opioid analgesics (oxycodone, tramadol, codeine) and opioid antagonists (naltrexone, naloxone)
  • Antiplatelet drugs (clopidogrel, aspirin)
  • Supplements with additive calming or GABA-active effects (GABA, L-Theanine, magnesium glycinate, valerian, kava, ashwagandha, glycine, taurine, high-dose melatonin)
  • Supplements with additive blood-thinning effects (high-dose fish oil, nattokinase, Ginkgo biloba, garlic extract, high-dose vitamin E, curcumin)
  • Immunosuppressants and immunomodulators (tacrolimus, ciclosporin, methotrexate, tumour necrosis factor inhibitors such as adalimumab)
  • Stacked peptides (Semax, BPC-157, TB-500, GHK-Cu)

Risk & Side Effects

  • High: Unverified identity, purity, and sterility of non-pharmaceutical product; absence of long-term and independent human safety data
  • Medium: Immunogenicity from aggregation and peptide-related impurities; additive central nervous system depression and symptom masking
  • Low: Local nasal irritation and altered smell or taste; injection-site reactions with subcutaneous use
  • Speculative: Unpredictable immune modulation in autoimmune disease or active malignancy; bleeding tendency; opioid-system involvement and reinforcement potential

Monitoring

Marker Target Why
Generalized Anxiety Disorder 7-item score (GAD-7) 0-4 Quantifies the primary target symptom
Perceived Stress Scale (PSS-10) Below 14 Captures subjective stress load, which anxiety scales miss
High-sensitivity C-reactive protein (hs-CRP) Below 1.0 mg/L, ideally below 0.5 mg/L General marker of body-wide inflammation; the most accessible read on the claimed immune-modulating effect
Interleukin-6 (IL-6) Below 1.5 pg/mL A signalling protein released by immune cells that Selank has been reported to shift in both directions
Complete blood count with differential (CBC) Lymphocytes 20-40% of white cells; neutrophil-to-lymphocyte ratio below 2.0 Detects immune shifts and screens for occult infection before an immune-active peptide is introduced
Comprehensive metabolic panel with liver enzymes (CMP, including ALT and AST) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 10-26 U/L Baseline liver and kidney function, essential before any non-pharmaceutical injectable
Thyroid-stimulating hormone (TSH) with free thyroxine (free T4) TSH 0.5-2.0 mIU/L; free T4 in the mid-to-upper reference range Thyroid dysfunction is a common, treatable cause of anxiety and fatigue that Selank would mask rather than correct
Ferritin 50-150 ng/mL in women; 50-200 ng/mL in men Depleted iron stores reproduce the fatigue and low drive Selank is used for
25-hydroxyvitamin D 40-60 ng/mL Low status is associated with low mood and impaired immune regulation, both relevant to the claimed mechanism
Fasting glucose and fasting insulin Glucose 75-85 mg/dL; insulin 2-5 µIU/mL Blood-sugar instability produces symptoms indistinguishable from anxiety; animal work reports Selank affects glucose and lipids
Morning serum cortisol 10-15 µg/dL at 8 a.m. Objective read on the stress-hormone axis Selank is claimed to buffer

Cadence: Full baseline panel and documented symptom score before the first dose; core panel repeated at the end of the first course (day 14 to 30), again at 3 months where courses are being repeated, then every 6 to 12 months across repeated cycles; symptom scores recorded weekly during a course.

Qualitative Assessment

  • Anxious arousal: frequency and intensity of racing thoughts, physical tension, and anticipatory worry
  • Sleep quality: time to fall asleep, night wakings, and how restored mornings feel
  • Cognitive clarity: ease of sustained focus, word-finding, and mental fatigue late in the working day
  • Energy and drive: willingness to initiate demanding tasks
  • Emotional range: whether calm arrives with or without flattening
  • Local tolerance: nasal stinging, dryness, congestion, or bleeding for the nasal route; site redness, swelling, or hardening for the injectable route